These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1112 related items for PubMed ID: 17405779

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains.
    Giovanetti E, Montanari MP, Mingoia M, Varaldo PE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1935-40. PubMed ID: 10428916
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.
    Bemer-Melchior P, Juvin ME, Tassin S, Bryskier A, Schito GC, Drugeon HB.
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2999-3002. PubMed ID: 11036012
    [Abstract] [Full Text] [Related]

  • 6. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin.
    Morosini MI, Cantón R, Loza E, del Campo R, Almaraz F, Baquero F.
    J Antimicrob Chemother; 2003 Jul; 52(1):50-5. PubMed ID: 12805254
    [Abstract] [Full Text] [Related]

  • 7. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates.
    Klugman KP, Capper T, Widdowson CA, Koornhof HJ, Moser W.
    J Antimicrob Chemother; 1998 Dec; 42(6):729-34. PubMed ID: 10052895
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
    Giovanetti E, Montanari MP, Marchetti F, Varaldo PE.
    J Antimicrob Chemother; 2000 Dec; 46(6):905-8. PubMed ID: 11102408
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F, Carnegy F, Willcock J, Amyes S.
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [Abstract] [Full Text] [Related]

  • 12. In vitro compared activity of telithromycin and azithromycin against northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
    Banche G, Roana J, Allizond V, Andreotti S, Malabaila A, Li Vigni N, Mandras N, Scalas D, Tullio V, Carlone NA, Savoia D, Gaido E, Barbui A, Cuffini AM.
    Lett Appl Microbiol; 2008 Oct; 47(4):309-14. PubMed ID: 19241525
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.
    Morosini MI, Cantón R, Loza E, Negri MC, Galán JC, Almaraz F, Baquero F.
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2427-31. PubMed ID: 11502509
    [Abstract] [Full Text] [Related]

  • 14. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
    Matic V, Kosowska K, Bozdogan B, Kelly LM, Smith K, Ednie LM, Lin G, Credito KL, Clark CL, McGhee P, Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
    [Abstract] [Full Text] [Related]

  • 15. [In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study].
    Gür D, Mülazimoğlu L, Unal S, e-BASKETT-II Calişma Grubu.
    Mikrobiyol Bul; 2007 Jan; 41(1):1-9. PubMed ID: 17427547
    [Abstract] [Full Text] [Related]

  • 16. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.
    Farrell DJ, Morrissey I, Bakker S, Felmingham D.
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():39-47. PubMed ID: 12239227
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.
    Jalava J, Kataja J, Seppälä H, Huovinen P.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):789-93. PubMed ID: 11181362
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.
    Schlegel L, Merad B, Rostane H, Broc V, Bouvet A.
    Clin Microbiol Infect; 2001 Jul; 7(7):362-6. PubMed ID: 11531981
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities.
    Ioannidou S, Tassios PT, Zachariadou L, Salem Z, Kanelopoulou M, Kanavaki S, Chronopoulou G, Petropoulou N, Foustoukou M, Pangalis A, Trikka-Graphakos E, Papafraggas E, Vatopoulos AC.
    Clin Microbiol Infect; 2003 Jul; 9(7):704-7. PubMed ID: 12925112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.